Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause the nerves themselves to deteriorate or become permanently damaged.

The global Multiple Sclerosis Therapeutics market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Multiple Sclerosis Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Multiple Sclerosis Therapeutics market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Multiple Sclerosis Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Multiple Sclerosis Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Novartis
Teva Pharmaceuticals
Sanofi Genzyme
Bayer
Pfizer
Biogen Idec
Merck
AbbVie

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
By drug
Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others
By Route of Administration
Oral
Injection

Segment by Application
Hospital Pharmacies
Retail Pharmacies
e-Commerce